Towards personalized therapy for patients with glioblastoma

Expert Review of Anticancer Therapy

Volumn 11, Issue 12, 2011, Pages 1935-1944

  Shirai, Katsuyuki ^a   Chakravarti, Arnab ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

elderly patients; glioblastoma; MGMT; personalized therapy; radiotherapy; targeting therapy; temozolomide

Indexed keywords

6 O BENZYLGUANINE; BEVACIZUMAB; BIOLOGICAL MARKER; BORTEZOMIB; CARMUSTINE; CILENGITIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; HYDROXYUREA; IMATINIB; IRINOTECAN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; TALAMPANEL; TEMOZOLOMIDE; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VORINOSTAT;

ANTIANGIOGENIC THERAPY; BLOOD TOXICITY; BRAIN HEMORRHAGE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURVIVAL; DIGESTIVE SYSTEM PERFORATION; DNA METHYLATION; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; ELDERLY CARE; GLIOBLASTOMA; HUMAN; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; PREDICTION; PROGNOSIS; QUALITY OF LIFE; RADIATION INJURY; RECURRENT CANCER; REVIEW; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT;

COMBINED MODALITY THERAPY; GLIOBLASTOMA; HUMANS; INDIVIDUALIZED MEDICINE;

EID: 82355184374     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.103     Document Type: Review

References (72)

1. Fisher JL, Schwartzbaum JA, Wrensch M, Wiemels JL. Epidemiology of brain tumors. Neurol. Clin. 25(4), 867-890 (2007). (Pubitemid 47603275)
2. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352(10), 987-996 (2005). (Pubitemid 40349501)
3. Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352(10), 997-1003 (2005). (Pubitemid 40349502)
4. Mirimanoff RO, Gorlia T, Mason W et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 Phase III randomized trial. J. Clin. Oncol. 24(16), 2563-2569 (2006). (Pubitemid 46630635)
5. Curran WJ Jr, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant gliomas trials. J. Natl. Cancer Inst. 85(9), 704-710 (1993). (Pubitemid 23133591)
6. Werner MH, Phuphanich S, Lyman GH. The increasing incidence of malignant gliomas and primary central nervous system lymphoma in the elderly. Cancer 76(9), 1634-1642 (1995).
7. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359(9311), 1011-1018 (2002). (Pubitemid 34286538)
8. Agarwala SS, Kirkwood JM. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist 5(2), 144-151 (2000). (Pubitemid 30238234)
9. Brada M, Hoang-Xuan K, Rampling R et al. Multicenter Phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann. Oncol. 12(2), 259-266 (2001). (Pubitemid 32223879)
10. Stupp R, Dietrich PY, Ostermann KS et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J. Clin. Oncol. 20(5), 1375-1382 (2002). (Pubitemid 34177445)
11. Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized Phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10(5), 4189-4199 (2009).
12. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 59(4), 793-797 (1999). (Pubitemid 29086728)
13. Hegi ME, Liu L, Herman JG et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J. Clin. Oncol. 26(25), 4189-4199 (2008).
14. Quinn JA, Pluda J, Dolan ME et al. Phase II trial of carmustine plus O6- benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J. Clin. Oncol. 20(9), 2277-2283 (2002). (Pubitemid 34441654)
15. Quinn JA, Jiang SX, Reardon DA et al. Phase II trial of temozolomide plus O6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J. Clin. Oncol. 27(8), 1262-1267 (2009).
16. Tolcher AW, Gerson SL, Denis L et al. Marked inactivation of O6-alkylguanine- DNA alkyltransferase activity with protracted temozolomide schedules. Br. J. Cancer 88(7), 1004-1011 (2003). (Pubitemid 36560766)
17. Clarke JL, Iwamoto FM, Sul J et al. Randomized Phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J. Clin. Oncol. 27(23), 3861-3867 (2009).
18. Brada M, Stenning S, Gabe R et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. J. Clin. Oncol. 28(30), 4601-4608 (2010).
19. Nicholas MK, Lukas RV, Jafri NF, Faoro L, Salgia R. Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas. Clin. Cancer Res. 12(24), 7261-7270 (2006). (Pubitemid 46095397)
20. Rich JN, Reardon DA, Peery T et al. Phase II trial of gefitinib in recurrent glioblastoma. J. Clin. Oncol. 22(1), 133-142 (2004). (Pubitemid 41095125)
21. van den Bent MJ, Brandes AA, Rampling R et al. Randomized Phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J. Clin. Oncol. 27(8), 1268-1274 (2009).
22. Chakravarti A, Berkey B, Robins H et al. An update of Phase II results from RTOG0211: a Phase I/II study of gefitinib with radiotherapy in newly diagnosed glioblastoma. J. Clin. Oncol. 24(Suppl. 18) 1527 (2006).
23. Brown PD, Krishnan S, Sarkaria JN et al. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J. Clin. Oncol. 26(34), 5603-5609 (2008).
24. Prados MD, Chang SM, Butowski N et al. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J. Clin. Oncol. 27(4), 579-584 (2009).
25. Stommel JM, Kimmelman AC, Ying H et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318(5848), 287-290 (2007). (Pubitemid 47574858)
26. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350(21), 2129-2139 (2004). (Pubitemid 38637993)
27. Marie Y, Carpentier AF, Omuro AM et al. EGFR tyrosine kinase domain mutations in human gliomas. Neurology 64(8), 1444-1445 (2005). (Pubitemid 40570519)
28. Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto Phase II clinical trials. J. Clin. Oncol. 17(8), 2572-2578 (1999). (Pubitemid 29368260)
29. Mellinghoff IK, Wang MY, Vivanco I et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 353(19), 2012-2024 (2005). (Pubitemid 41609094)
30. Haas-Kogan DA, Prados MD, Tihan T et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J. Natl. Cancer. Inst. 97(12), 880-887 (2005). (Pubitemid 41417939)
31. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat. Med. 9(6), 669-676 (2003). (Pubitemid 36749215)
32. Stefanik DF, Fellows WK, Rizkalla LR et al. Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft. J. Neurooncol. 55(2), 91-100 (2001). (Pubitemid 34065325)
33. Bao S, Wu Q, Sathornsumetee S et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res. 66(16), 7843-7848 (2008).
34. Vredenburgh JJ, Desjardins A, Herndon JE II et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol. 25(30), 4722-4729 (2007). (Pubitemid 350086473)
35. Prados MD, Lamborn K, Yung WK et al. A Phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro. Oncol. 8(2), 189-193 (2006). (Pubitemid 46542664)
36. Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 27(28), 4733-4740 (2009).
37. Kreisl TN, Kim L, Moore K et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol. 27(5), 740-745 (2009).
38. Chi AS, Norden AD, Wen PY. Antiangiogenic strategies for treatment of malignant gliomas. Neurotherapeutics 6(3), 513-526 (2009).
39. Chen W, Delaloye S, Silverman DH et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J. Clin. Oncol. 25(30), 4714-4721 (2007). (Pubitemid 350086472)
40. Sathornsumetee S, Cao Y, Marcello JE et al. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J. Clin. Oncol. 26(2), 271-278 (2008).
41. Lai A, Filka E, McGibbon B et al. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int. J. Radiat. Oncol. Biol. Phys. 71(5), 1372-1380 (2008).
42. Lai A, Tran A, Nghiemphu PL et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J. Clin. Oncol. 29(2), 142-148 (2011).
43. Raymond E, Brandes AA, Dittrich C et al. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group study. J. Clin. Oncol. 26(28), 4659-4665 (2008).
44. Dresemann G, Weller M, Rosenthal MA et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. J. Neurooncol. 96(3), 393-402 (2010).
45. Dai H, Marbach P, Lemaire M, Hayes M, Elmquist WF. Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J. Pharmacol. Exp. Ther. 304(3), 1085-1092 (2003). (Pubitemid 36254421)
46. Howes JF, Bell C. Talampanel. Neurotherapeutics 4(1), 126-129 (2007). (Pubitemid 46107320)
47. Ishiuchi S, Tsuzuki K, Yoshida Y et al. Blockage of Ca2+-permeable AMPA receptors suppresses migration and induces apoptosis in human glioblastoma cells. Nat. Med. 8(9), 971-978 (2002). (Pubitemid 35033701)
48. Grossman SA, Ye X, Chamberlain M et al. Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter Phase II trial. J. Clin. Oncol. 27(25), 4155-4161 (2009).
49. Yamada S, Bu XY, Khankaldyyan V, Gonzales-Gomez I, McComb JG, Laug WE. Effect of the angiogenesis inhibitor cilengitide (EMD 121974) on glioblastoma growth in nude mice. Neurosurgery 59(6), 1304-1312 (2006). (Pubitemid 44949775)
50. Reardon DA, Fink KL, Mikkelsen T et al. Randomized Phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J. Clin. Oncol. 26(34), 5610-5617 (2008).
51. Stupp R, Hegi ME, Neyns B et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 28(16), 2712-2718 (2010).
52. Stupp R, Van Den Bent M, Erridge S et al. Cilengitide in newly diagnosed glioblastoma with MGMT promoter methylation: protocol of a multicenter, randomized, open-label, controlled Phase III trial (CENTRIC). J. Clin. Oncol. 28(Suppl. 15) (2010) (Abstract TPS152).
53. Nabors L, Fink K, Reardon D et al. Cilengitide in patients with newly diagnosed glioblastoma multiforme and unmethylated MGMT gene promoter: protocol of a multicenter, randomized, open-label, controlled Phase II study. J. Clin. Oncol. 28(Suppl. 15) (2010) (Abstract TPS151).
54. Yin D, Zhou H, Kumagai T et al. Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene 24(3), 344-354 (2005). (Pubitemid 40188583)
55. Koschny R, Holland H, Sykora J et al. Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Clin. Cancer Res. 13(11), 3403-3412 (2007). (Pubitemid 46944929)
56. Kubicek GJ, Werner-Wasik M, Machtay M et al. Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies. Int. J. Radiat. Oncol. Biol. Phys. 74(2), 433-439 (2009).
57. Yin D, Ong JM, Hu J et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo. Clin Cancer Res. 13(3), 1045-1052 (2007). (Pubitemid 46340384)
58. Galanis E, Jaeckle KA, Maurer MJ et al. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J. Clin. Oncol. 27(12), 2052-2058 (2009).
59. Grossman SA, Ye X, Piantadosi S et al. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin. Cancer. Res. 16(8), 2443-2449 (2010).
60. Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N. Engl. J. Med. 356(15), 1527-1535 (2007). (Pubitemid 46588417)
61. Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J. Clin. Oncol. 22(9), 1583-1588 (2004). (Pubitemid 41079795)
62. Lutterbach J, Ostertag C. What is the appropriate radiotherapy protocol for older patients with newly diagnosed glioblastoma? J. Clin. Oncol. 23(12), 2869-2870 (2005). (Pubitemid 46179485)
63. Glantz M, Chamberlain M, Liu Q, Litofsky NS, Recht LD. Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas. Cancer 97(9), 2262-2266 (2003). (Pubitemid 36444070)
64. Chinot OL, Barrie M, Frauger E et al. Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations. Cancer 100(10), 2208-2214 (2004). (Pubitemid 38580342)
65. Malmstrom A, Grønberg BH, Stupp R et al. Glioblastoma (GBM) in elderly patients: a randomized Phase III trial comparing survival in patients treated with 6-week radiotherapy (RT) versus hypofractionated RT over 2 weeks versus temozolomide single-agent chemotherapy (TMZ). J. Clin. Oncol. 28(Suppl. 18) (2010) (Abstract LBA2002).
66. Wick W, Engel C, Combs SE et al. NOA-08 randomized Phase III trial of 1-week-on/1-week-off temozolomide versus involved-field radiotherapy in elderly (older than age 65) patients with newly diagnosed anaplastic astrocytoma or glioblastoma (Methusalem). J. Clin. Oncol. 28(Suppl. 18) (2010) (Abstract LBA2001).
67. Brandes AA, Vastola F, Basso U et al. A prospective study on glioblastoma in the elderly. Cancer 97(3), 657-662 (2003). (Pubitemid 36125843)
68. Combs SE, Wagner J, Bischof M et al. Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients. Int. J. Radiat. Oncol. Biol. Phys. 70(4), 987-992 (2008). (Pubitemid 351296114)
69. Brandes AA, Franceschi E, Tosoni A et al. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer 115(15), 3512-3518 (2009).
70. Batchelor TT, Betensky RA, Esposito JM et al. Age-dependent prognostic effects of genetic alterations in glioblastoma. Clin. Cancer Res. 10(1), 228-233 (2004). (Pubitemid 38114184)
71. Roa W, Xing JZ, Small C et al. Current developments in the radiotherapy approach to elderly and frail patients with glioblastoma multiforme. Expert Rev. Anticancer Ther. 9(11), 1643-1650 (2009).
72. Dowsett M, Dunbier AK. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin. Cancer Res. 14(24), 8019-8026 (2008).